Research Team Led by Pacific Biomarkers, Inc. VP Amar Sethi Identifies Two Potential Diagnostic Markers for Ischemic Heart Disease
Published: Jul 22, 2010
SEATTLE, WA--(Marketwire - July 22, 2010) - Dr. Amar Sethi, VP of Science and Technology at Pacific Biomarkers, Inc. (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology, and diagnostics industries, is the lead author of a research study published in the July issue of the journal Clinical Chemistry. The study identifies the potential use of two diagnostic markers for ischemic heart disease.
Dr. Sethi compared patients with ischemic heart disease and either high or low HDL-cholesterol levels with subjects without ischemic heart disease matched by HDL-C levels, age, and gender. The study found that the levels of pre beta1-HDL, a nascent apoA-I particle, were twice as high in individuals with ischemic heart disease as compared to those with no heart disease in both the high and low HDL-C groups. Dr. Sethi reports that patients with elevated pre beta1-HDL also exhibited low Lecithin:Cholesterol Acyltransferase (LCAT) activity. LCAT is an enzyme important for the packaging of cholesterol into HDL particles and thus for the successful removal of excess cholesterol from the body. The results show that a combined assessment of both pre beta1-HDL levels and LCAT activity yield correct classification of patients with ischemic heart disease in more than 90% of cases, which is much higher than other conventional risk factors. Thus, pre beta1-HDL concentrations and LCAT activity levels are potentially useful diagnostic markers for ischemic heart disease.
"These results indicate that the development of IHD may be more closely related to a combination of multiple factors in the reverse cholesterol transport pathway rather than one particular metric, such as HDL-C. Our study suggests that the measurement of pre beta1-HDL and LCAT as additional tests could be useful in identifying a subset of patients that are at risk for IHD, which otherwise would not have been identified," said Dr. Sethi.
Dr. Sethi adds, "These same biomarkers are also important tools in the in-direct assessment of the HDL particle's function as they provide crucial information about the overall efficiency of the HDL particle's ability to remove cholesterol from the body. Direct measures of HDL functionality for clinical labs and pharmaceutical companies developing HDL raising drugs are still warranted and will hopefully be accomplished in the near future by more sophisticated high throughput biomarkers of HDL function from Pacific Biomarkers, Inc."
Ron Helm, Chief Executive Officer and Chairman of Pacific Biomarkers, said, "This research study represents a significant advance in our understanding of the potential use of diagnostic markers for ischemic heart disease. In so doing, it sheds light on a market opportunity that may enable the Company to extend its goals of providing the most comprehensive set of biomarker laboratory services to the industries we serve."
About Pacific Biomarkers, Inc.
Established in 1989, PBI provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, cell-based assays, mass spectrometry, and multiplex testing.
PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBMC."
For more information about PBI, visit the company's web site at www.pacbio.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release includes forward-looking statements including, but not limited to, the following: growth in revenues and backlog; results of business development activities; financial results; future growth; and the viability and acceptance of its established and new services, including the Company's biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company's ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company's ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2009).
Pacific Biomarkers, Inc.
The Investor Relations Group